So far three main human estrogen receptors (ERα, ERβ and GPER) have been identified as potential targets for tailored endocrine therapies to treat ovarian cancer, although these approaches have not been implemented into clinical routine so far. This evidence concerns the gene ESR2 and ovarian cancer.